Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023, and is expected to increase a significant CAGR by 2034, estimates DelveInsight
Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook
Key Takeaways from the Postpartum Depression Market Report
In May 2025, Nanjing Minova Pharmaceutical Co., Ltd. announced a study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine： To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules.
In May 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023.
In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2034.
Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market.
Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023
Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2034.
The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Stay ahead in the Postpartum Depression Therapeutics Market with DelveInsight's Strategic Report @ Postpartum Depression Treatment Market
Postpartum Depression Epidemiology
Total Diagnosed Prevalent Population of Maternal Postpartum Depression
Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence
Postpartum Depression Marketed Therapies
ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
ZULRESSO: Sage Therapeutics
ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.
Postpartum Depression Emerging Therapies
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.
To learn more about Postpartum Depression Treatment guidelines, visit @ Postpartum Depression Clinical Trials Assessment
Postpartum Depression Market Outlook
Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.
Postpartum Depression Treatment Landscape
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.
Scope of the Postpartum Depression Market Report
Coverage- 7MM
Study Period- 2020-2034
Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
Postpartum Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. Report Introduction
3. Postpartum Depression Market Overview at a Glance
4 Executive Summary of Postpartum Depression
5 Key events
6 Disease Background and Overview
7 Treatment and Management
8 Methodology
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Postpartum Depression (PPD): Seven Major Market Analysis
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
20 hours ago
- National Post
'They make you doubt your sanity.' Staff describe toxic workplace at top mental health hospital
Many staff inside the country's leading mental health institution say they are suffering their own trauma from a toxic workplace rife with discrimination and bullying. Article content Anonymous employee feedback from health-care providers at Toronto's Centre for Addiction and Mental Health (CAMH) include widespread staff complaints about a work culture they say left them with mental health challenges including anxiety, depression and even suicidality. Article content Article content Article content When they attempt to address their grievances, many say they were met with retaliation and a lack of accountability. Article content Article content Some staff blamed the workplace culture at CAMH for mental health challenges. 'They make you doubt your sanity,' one respondent wrote. Article content Some respondents explicitly noted a gap between the hospital's mental health mission and the psychological state of its employees. Article content 'It is ironic that an organization that provides mental health support is so disconnected from the mental health of its staff,' said one respondent. Article content Another wrote: 'The fact that the organization puts out statements about anti-racism that don't align with what we experience internally, it's a problem. They don't walk the talk internally.' Article content CAMH, hailed as a leading international mental health voice that provides training on staff mental health to major employers in Canada, said it has reviewed the criticisms by staff and taken active steps to address them. Article content 'I know this is what happens in workplaces — It is very different when you hear it from colleagues,' said CAMH equity director, Kwame McKenzie in an interview. 'It's very poignant. It's very raw. It makes you think of the urgency that you need to do something different.' Article content Article content The responses were gathered in 2021 and 2023 by an external consulting group and the hospital's equity office respectively, and were obtained by the Investigative Journalism Bureau through freedom of information legislation. Article content The internal reviews, which unfolded during COVID and the emergence of the Black Lives Matter movement, are only the latest attempts to understand longstanding issues at CAMH. Article content Following a 2019 internal survey that raised concerns of racism, hospital administrators decided additional indepth interviews were needed to better understand the experience of employees. In 2021 and 2023, a total of about 2,000 employees — nearly half the hospital's staff — took part in separate workplace reviews.
Globe and Mail
a day ago
- Globe and Mail
Juvenile Idiopathic Arthritis Therapeutic Landscape Shifts as Biologics and JAK Inhibitors Drive Significant Growth
The Juvenile Idiopathic Arthritis market is entering a period of robust expansion, underpinned by increasing awareness, advances in diagnostics, and a wave of novel therapeutics from leading pharmaceutical and biotech companies, such as Novartis, Roche (Chugai Pharmaceutical), AbbVie, AstraZeneca, Pfizer, Eli Lilly, and Incyte Corporation. DelveInsight's report, ' Juvenile Idiopathic Arthritis Market Insight, Epidemiology and Market Forecast – 2032,' reveals that the Juvenile Idiopathic Arthritis therapeutic landscape across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom and Japan is growing noticeably, underpinned by advancements in targeted therapies (such as biologics and JAK inhibitors), increased investment in research and development, and the introduction of innovative diagnostic tools. The United States holds the largest market share in terms of both revenue and patient pool across 7MM, primarily due to better diagnosis, the highest pharmaceutical spending per capita globally, and significant drug development efforts with the presence of major Juvenile Idiopathic Arthritis drug companies in the country. Download the Juvenile Idiopathic Arthritis Market report to understand market dynamics and treatment landscape trends. DelveInsight's epidemiological modelling underscores that Juvenile Idiopathic Arthritis, the most common chronic rheumatic disease of childhood, continues to present significant clinical and economic challenges across the 7MM. Studies show that females are generally more affected than males by Juvenile Idiopathic Arthritis, although this trend varies depending on the specific subtype, with enthesitis-related JIA notably showing a male predominance. Furthermore, the DelveInsight report details country-specific diagnosed Juvenile Idiopathic Arthritis patient pools from 2019 to 2032 and highlights a steady upward trend driven by heightened diagnostic vigilance and improved registry coverage. Notably, the United States captures the largest share of identified Juvenile Idiopathic Arthritis cases, whereas Germany leads within the European countries, reflecting regional variations in paediatric rheumatology infrastructure and reporting mechanisms. Discover evolving trends in the Juvenile Idiopathic Arthritis patient pool forecasts @ Juvenile Idiopathic Arthritis Epidemiology Analysis. The Juvenile Idiopathic Arthritis treatment landscape has evolved considerably, transitioning from conventional non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) to sophisticated biologic and targeted synthetic agents that inhibit key inflammatory pathways. Although methotrexate retains a central role as an anchor DMARD, an expanding class of tumour necrosis factor (TNF) inhibitors, interleukin (IL) blockers and Janus kinase (JAK) inhibitors has reshaped the Juvenile Idiopathic Arthritis therapeutic paradigm, offering clinicians greater flexibility for refractory disease. According to the DelveInsight report, the Juvenile Idiopathic Arthritis therapies pipeline shows promising development activity. New developments in Juvenile Idiopathic Arthritis therapies are focused on targeted approaches, particularly JAK inhibitors. Tofacitinib and baricitinib are two JAK inhibitors that have been approved for use in specific Juvenile Idiopathic Arthritis subtypes, primarily in cases where patients haven't responded well to other treatments like TNF inhibitors. Baricitinib, for instance, has shown efficacy in patients with polyarticular Juvenile Idiopathic Arthritis, extended oligoarticular Juvenile Idiopathic Arthritis, enthesitis-related arthritis, and psoriatic Juvenile Idiopathic Arthritis aged 2 to 18 years. Tofacitinib has also been shown to be effective in patients with polyarticular course Juvenile Idiopathic Arthritis. Furthermore, the competitive intelligence section of the report highlights novel agents targeting cytokine signalling beyond TNF and IL-6, as well as next-generation oral molecules designed to optimise patient adherence. Robust evaluation of launch timelines, annual cost of therapy, and forecast clinical differentiation suggests a wave of innovative entrants that could meaningfully expand the Juvenile Idiopathic Arthritis drugs in the coming decade. Dive Deeper into the evolving treatment landscape @ Juvenile Idiopathic Arthritis Emerging Therapies. Key opinion leader insights collected through primary research validate these trends and pinpoint persistent gaps such as limited treatment options for systemic Juvenile Idiopathic Arthritis flares, glucocorticoid sparing strategies, and long-term safety surveillance in growing children. KOLs also emphasise the need for biomarkers that can guide personalised therapeutic sequencing and predict disease trajectory, a frontier that remains largely unaddressed despite significant scientific advances. Addressing these challenges offers significant opportunities for innovative biotech and pharma entities to carve out competitive advantages in an increasingly crowded market landscape. Looking ahead, the Juvenile Idiopathic Arthritis market is poised to benefit from deeper understanding of disease pathogenesis, breakthrough device-assisted drug-delivery platforms and collaborative research networks that accelerate paediatric trial recruitment. While significant strides have been made, continued innovation in immune-modulation, tolerability optimisation and health-equity initiatives will be essential to fully meet the unmet needs of this vulnerable patient population. Stakeholders who leverage DelveInsight's granular insights stand to capitalise on the forthcoming wave of therapeutic progress and capture value in a market primed for transformative growth through 2032. Table of Contents 1. Key Insights 2. Executive Summary of Juvenile Idiopathic Arthritis 3. Competitive Intelligence Analysis for Juvenile Idiopathic Arthritis 4. Juvenile Idiopathic Arthritis Market Overview at a Glance 5. Juvenile Idiopathic Arthritis: Disease Background and Overview 6. Juvenile Idiopathic Arthritis Patient Journey 7. Juvenile Idiopathic Arthritis Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Juvenile Idiopathic Arthritis Unmet Needs 10. Key Endpoints of Juvenile Idiopathic Arthritis Treatment 11. Juvenile Idiopathic Arthritis Marketed Products 12. Juvenile Idiopathic Arthritis Emerging Therapies 13. Juvenile Idiopathic Arthritis: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Juvenile Idiopathic Arthritis 17. KOL Views 18. Juvenile Idiopathic Arthritis Market Drivers 19. Juvenile Idiopathic Arthritis Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Juvenile Idiopathic Arthritis Pipeline Insight Juvenile Idiopathic Arthritis pipeline insight provides comprehensive insights about the Juvenile Idiopathic Arthritis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Juvenile Idiopathic Arthritis companies, including Novartis, Roche, AbbVie, AstraZeneca, Pfizer, Eli Lilly, and Incyte Corporation, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
CTV News
2 days ago
- CTV News
Gateways Counselling – How staying active in nature can help mental wellbeing
Regina Watch Gateways Counselling's Ramona Wijesinghe shares with us some of the benefits with staying active in nature and how it helps improve mental health. #SponsoredContent
